# Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites

> **NCT03230708** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hui ting Xu，MD** · enrollment: 18 (estimated)

## Conditions studied

- Malignant Ascites

## Interventions

- **OTHER:** Erythrocytes derived MPs containing MTX
- **DRUG:** convention drugs

## Key facts

- **NCT ID:** NCT03230708
- **Lead sponsor:** Hui ting Xu，MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2017-12-01
- **Final completion:** 2018-02-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230708, "Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03230708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*